JoelWNealMDPhD

Oncology • Stanford, CA

Assistant Professor, Medicine - Oncology, Stanford University Medical Center

Join to view full profile

Dr. Neal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Neal's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Fax+1 650-498-5840

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2007 - 2010
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2004 - 2007
Northwestern University The Feinberg School of MedicineClass of 2004

Certifications & Licensure

CA State Medical License 2010 - 2025
MA State Medical License 2006 - 2011
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations Start of enrollment: 2009 Oct 01
Active, not recruiting
Phase 2
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Start of enrollment: 2011 Jun 01
Completed
Phase 2
Molecular Analysis of Thoracic Malignancies Start of enrollment: 2011 Aug 01
Enrolling by invitation
Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Start of enrollment: 2011 Oct 01
Completed
Phase 2
Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors Start of enrollment: 2012 Oct 01
Terminated
Phase 2
Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2016 Oct 01
Active, not recruiting
Phase 2
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) Start of enrollment: 2021 Apr 08
Recruiting
Phase 2
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations Start of enrollment: 2020 Jan 10
Active, not recruiting
Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

833 citations
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Julien Mazieres, Alexander Drilon, Amélie Lusque, Laurent Mhanna, Alexis B. Cortot
Annals of Oncology. 2019-08-01
368 citations
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Zofia Piotrowska, Matthew J. Niederst, Chris Karlovich, Heather A. Wakelee, Joel W. Neal
Cancer Discovery. 2015-05-01
256 citations
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
Nicolas Marcoux, Scott N. Gettinger, Grainne M. O'Kane, Kathryn C. Arbour, Joel W. Neal
Journal of Clinical Oncology. 2019-02-01

Lectures

Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Other

Personalized, genotype-directed therapy for advanced non-small cell lung cancer
Neal JW, Sequist LV
http://www.uptodate.com/contents/personalized-genotype-directed-therapy-for-advanced-non-small-cell-
UpToDate, Wolters Kluwer Health - 2013-02-25

Press Mentions

Exelixis Announces Results from COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Multiple Advanced Solid Tumor TypesMay 13th, 2020
Sequencing Switches, Intriguing Combos Being Debated in ALK+ NSCLCAugust 8th, 2017
Presents State of the Science Summit™: Updates in Management of Adenocarcinoma of the LungJune 12th, 2017
Join now to see all